StockNews.com Downgrades Jazz Pharmaceuticals (NASDAQ:JAZZ) to Hold

StockNews.com downgraded shares of Jazz Pharmaceuticals (NASDAQ:JAZZGet Rating) from a buy rating to a hold rating in a report issued on Tuesday.

JAZZ has been the topic of several other reports. UBS Group began coverage on Jazz Pharmaceuticals in a report on Monday, June 13th. They issued a buy rating and a $194.00 target price on the stock. Cowen boosted their price target on shares of Jazz Pharmaceuticals from $200.00 to $225.00 in a research report on Thursday, May 5th. The Goldman Sachs Group cut shares of Jazz Pharmaceuticals from a buy rating to a neutral rating and cut their price objective for the company from $202.00 to $196.00 in a research report on Wednesday, April 6th. Piper Sandler decreased their price target on shares of Jazz Pharmaceuticals from $197.00 to $193.00 in a research note on Thursday, May 5th. Finally, Cowen lifted their price target on shares of Jazz Pharmaceuticals from $200.00 to $225.00 in a report on Thursday, May 5th. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of Moderate Buy and an average price target of $203.69.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ opened at $153.72 on Tuesday. The company has a market cap of $9.60 billion, a PE ratio of -180.84, a price-to-earnings-growth ratio of 1.26 and a beta of 0.69. The company has a current ratio of 3.39, a quick ratio of 2.06 and a debt-to-equity ratio of 1.66. The stock has a 50-day moving average price of $153.10 and a 200-day moving average price of $151.63. Jazz Pharmaceuticals has a 12-month low of $117.64 and a 12-month high of $169.98.

Jazz Pharmaceuticals (NASDAQ:JAZZGet Rating) last announced its quarterly earnings results on Wednesday, May 4th. The specialty pharmaceutical company reported $3.13 EPS for the quarter, topping analysts’ consensus estimates of $3.00 by $0.13. Jazz Pharmaceuticals had a positive return on equity of 24.44% and a negative net margin of 1.49%. The business had revenue of $813.72 million for the quarter, compared to analysts’ expectations of $853.73 million. During the same period in the previous year, the firm earned $3.42 EPS. The business’s quarterly revenue was up 33.9% on a year-over-year basis. As a group, equities analysts forecast that Jazz Pharmaceuticals will post 14.74 earnings per share for the current fiscal year.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 8,775 shares of the business’s stock in a transaction on Tuesday, July 5th. The shares were sold at an average price of $157.28, for a total value of $1,380,132.00. Following the transaction, the chief executive officer now directly owns 351,912 shares of the company’s stock, valued at approximately $55,348,719.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO Bruce C. Cozadd sold 8,775 shares of the company’s stock in a transaction on Tuesday, July 5th. The shares were sold at an average price of $157.28, for a total transaction of $1,380,132.00. Following the completion of the sale, the chief executive officer now directly owns 351,912 shares of the company’s stock, valued at approximately $55,348,719.36. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Anne Oriordan sold 466 shares of the company’s stock in a transaction on Monday, May 9th. The stock was sold at an average price of $148.95, for a total transaction of $69,410.70. Following the sale, the director now directly owns 9,245 shares of the company’s stock, valued at $1,377,042.75. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 51,564 shares of company stock worth $7,949,626. 4.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of institutional investors have recently modified their holdings of the stock. Gateway Investment Advisers LLC grew its position in Jazz Pharmaceuticals by 0.4% in the 1st quarter. Gateway Investment Advisers LLC now owns 15,277 shares of the specialty pharmaceutical company’s stock worth $2,378,000 after purchasing an additional 64 shares during the last quarter. Fifth Third Bancorp grew its position in Jazz Pharmaceuticals by 32.9% in the 2nd quarter. Fifth Third Bancorp now owns 279 shares of the specialty pharmaceutical company’s stock worth $44,000 after purchasing an additional 69 shares during the last quarter. CWM LLC grew its position in Jazz Pharmaceuticals by 25.2% in the 1st quarter. CWM LLC now owns 422 shares of the specialty pharmaceutical company’s stock worth $66,000 after purchasing an additional 85 shares during the last quarter. Captrust Financial Advisors grew its position in Jazz Pharmaceuticals by 2.4% in the 1st quarter. Captrust Financial Advisors now owns 3,707 shares of the specialty pharmaceutical company’s stock worth $577,000 after purchasing an additional 86 shares during the last quarter. Finally, Securian Asset Management Inc. boosted its holdings in shares of Jazz Pharmaceuticals by 1.8% in the fourth quarter. Securian Asset Management Inc. now owns 5,523 shares of the specialty pharmaceutical company’s stock valued at $704,000 after acquiring an additional 100 shares in the last quarter. Institutional investors and hedge funds own 93.23% of the company’s stock.

Jazz Pharmaceuticals Company Profile

(Get Rating)

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors.

Featured Articles

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.